Nov 09, 2022 / 05:50PM GMT
Jin Law - Crédit Suisse AG - Research Division - Senior Analyst
Okay. We're going to get started. My name is Rich Law. I'm a senior biotech analyst at CS. I'd like to welcome our -- Kymera for next fireside chat. We're joined by Nello Mainolfi, CEO. Nello, welcome.
Nello Mainolfi - Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Thanks, Richard. Thanks for the invite.
Jin Law - Crédit Suisse AG - Research Division - Senior Analyst
So before we jump into Q&A, any opening remarks from you?
Nello Mainolfi - Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Yes. So first, thanks for the invitation. Beautiful location. Luckily, today is a good day.
I just want to remind everybody, Kymera is a company focused on taking targeted protein degradation and building a fully integrated commercial-stage biotech in a disease-agnostic and technology-agnostic manner. Obviously, we've
Kymera Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot